Pfizer n’est pas si serein, dans son dernier rapport aux actionnaires il alerte :

The Q4 earnings report explains to investors that there could be “unfavorable new pre-clinical, clinical or safety data and further analyses of existing pre-clinical, clinical or safety data or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection”.